1,018 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,018 shares of the company’s stock, valued at approximately $86,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AXSM. Raiffeisen Bank International AG acquired a new position in Axsome Therapeutics during the fourth quarter worth about $51,000. Assetmark Inc. bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $52,000. R Squared Ltd acquired a new position in Axsome Therapeutics during the 4th quarter worth approximately $64,000. Aquatic Capital Management LLC bought a new position in Axsome Therapeutics in the 4th quarter valued at approximately $76,000. Finally, KBC Group NV lifted its stake in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after purchasing an additional 385 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark Coleman sold 3,000 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $107.49, for a total transaction of $322,470.00. Following the completion of the sale, the director now directly owns 54,137 shares in the company, valued at $5,819,186.13. This represents a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 22.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 29th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $165.00 target price (up previously from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, February 18th. Robert W. Baird boosted their price target on Axsome Therapeutics from $160.00 to $162.00 and gave the stock an “outperform” rating in a report on Tuesday, May 6th. Finally, Truist Financial upped their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $172.14.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $105.07 on Tuesday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics, Inc. has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The company has a 50 day simple moving average of $108.44 and a two-hundred day simple moving average of $106.00. The company has a market capitalization of $5.17 billion, a PE ratio of -17.54 and a beta of 0.46.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.